FDA Approval: Serdexmethylphenidate/Dexmethylphenidate for Adult ADHD Treatment
November 14th 2022Theresa Cerulli, MD, describes the indication and mechanism of the recent FDA approved combination product serdexmethylphenidate /dexmethylphenidate for the treatment of attention deficit/hyperactivity disorder (ADHD).
Treatment Resistance in Youths With ADHD and Comorbid Conditions
October 1st 2007Since its introduction in DSM-III in 1980, attention-deficit/ hyperactivity disorder (ADHD) has proved to be a developmental disorder with many causes and complex behavioral, cognitive, and emotional manifestations that can impair academic functioning, occupational achievement, social relationships, and self-esteem.